| __timestamp | Novavax, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79435000 | 293000 |
| Thursday, January 1, 2015 | 162644000 | 1002000 |
| Friday, January 1, 2016 | 237939000 | 888000 |
| Sunday, January 1, 2017 | 168435000 | 19623000 |
| Monday, January 1, 2018 | 173797000 | 30421000 |
| Tuesday, January 1, 2019 | 113842000 | 34794000 |
| Wednesday, January 1, 2020 | 747027000 | 28304000 |
| Friday, January 1, 2021 | 2534508000 | 56886000 |
| Saturday, January 1, 2022 | 1235278000 | 100894000 |
| Sunday, January 1, 2023 | 737502000 | 159765000 |
Data in motion
In the competitive landscape of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, Novavax, Inc. has consistently outpaced Viridian Therapeutics, Inc. in R&D spending. From 2014 to 2023, Novavax's R&D expenses surged by over 900%, peaking in 2021 with a staggering 2.5 billion dollars, driven by its pivotal role in COVID-19 vaccine development. In contrast, Viridian's R&D investments, while growing, remained more modest, increasing by approximately 54 times over the same period, reflecting its focused approach in niche therapeutic areas. This disparity highlights Novavax's aggressive strategy to capture market share through innovation, while Viridian maintains a steady, targeted investment in its pipeline. As the biotech sector evolves, these strategic choices will shape the future trajectories of both companies.
Eli Lilly and Company vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
AbbVie Inc. vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Novartis AG vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.
Bio-Techne Corporation or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc.
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs Novavax, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Comparing Innovation Spending: Geron Corporation and Viridian Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.